Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Clearside Biomedical ( (CLSDQ) ) is now available.
On December 8, 2025, Clearside Biomedical filed a Form 25 with the SEC to delist its common stock from Nasdaq and terminate its registration under the Exchange Act, following a voluntary Chapter 11 bankruptcy filing. The stock was suspended from Nasdaq trading on December 1, 2025, and began trading on the OTC Pink Limited Market, with the delisting process expected to reduce certain SEC reporting obligations.
The most recent analyst rating on (CLSDQ) stock is a Sell with a $0.78 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSDQ Stock Forecast page.
Spark’s Take on CLSDQ Stock
According to Spark, TipRanks’ AI Analyst, CLSDQ is a Underperform.
The overall stock score is heavily influenced by Clearside Biomedical’s poor financial performance, characterized by declining revenues, consistent losses, and negative equity. Technical analysis also indicates bearish momentum, with the stock trading below key moving averages and showing oversold conditions. The valuation is unattractive due to a negative P/E ratio and no dividend yield.
To see Spark’s full report on CLSDQ stock, click here.
More about Clearside Biomedical
Clearside Biomedical, Inc. operates in the biopharmaceutical industry, focusing on developing treatments for eye diseases. The company specializes in therapies that are administered through the suprachoroidal space, targeting retinal diseases.
Average Trading Volume: 260,574
Technical Sentiment Signal: Sell
Current Market Cap: $4.13M
For detailed information about CLSDQ stock, go to TipRanks’ Stock Analysis page.